iluvien

Generic: fluocinolone acetonide intravitreal implant·Brand: Iluvien

iluvien: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
ALIMERA SCIENCES INC (ALIM)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE ILUVIEN is a corticosteroid indicated for: the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1.1) the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1.2) 1.1 Diabetic Macular Edema ILUVIEN ® is indicated for the treatment of diabetic macular edema (DME) in patients who have been previou(ALIM)

Frequently asked questions

Who is developing iluvien?

iluvien is being developed by ALIMERA SCIENCES INC.

What is iluvien's latest FDA decision?

The most recent tracked FDA decision for iluvien is Approval for 1 INDICATIONS AND USAGE ILUVIEN is a corticosteroid indicated for: the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1.1) the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1.2) 1.1 Diabetic Macular Edema ILUVIEN ® is indicated for the treatment of diabetic macular edema (DME) in patients who have been previou, dated September 26, 2014.

Get deeper analysis on iluvien

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis